Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott
Executive Summary
Actavis’ purchase of Warner Chilcott will lower the former’s overall tax rate significantly, expand its specialty pharma business to 25% of total revenues, and provide global critical mass – all necessary responses to a future that includes fewer opportunities for small molecule generics and greater pricing pressures.
You may also be interested in...
How US Tax Plan Could Affect Global Pharma Manufacturing Networks
Allergan, Pfizer, Bristol-Myers Squibb, AbbVie, GSK, Sanofi and Roche showed glimpses in recent earnings calls of potential impacts on their global manufacturing networks from a US plan to legislate border-adjusted tax cuts. But there was not a word about President Trump’s threat of tariffs.
Biotech And Specialty Pharma’s M&A Power Gains On Big Pharma, EY Report
Big pharma continues to have the most buying power, according to EY’s annual M&A report, but the buying power of big biotech and specialty pharma grew significantly more.
Teva Loses 180-Day Exclusivity For Generic Actonel As FDA Stands Firm On Review Delays
Mylan’s product launches as FDA tells Teva that the agency’s delay in granting tentative ANDA approval does not prevent forfeiture of exclusivity.